Partner, Frazier Healthcare Partners
Dan Estes is a Partner on the Life Sciences team at Frazier Healthcare Partners and has been at Frazier since 2011. He focuses primarily on investing in and helping to launch early-stage companies developing novel therapeutics. Dan serves on the boards of Arcutis, Semnur Pharmaceuticals, Outpost Medicine, Sierra Oncology (NASDAQ: SRRA), and Cirius Therapeutics. He has also been involved in Frazier’s investments in Acerta (acquired by AstraZeneca), Tobira Therapeutics (acquired by Allergan), Ignyta (acquisition by Roche pending), PreCision Dermatology (acquired by Valeant), and Allena (NASDAQ: ALNA). Prior to joining Frazier, Dan was a management consultant with McKinsey & Company’s healthcare practice, where he worked with leading pharmaceutical companies on R&D and business development strategies. Dan received his Ph.D. in Biomedical Engineering from the University of Michigan, where his doctoral research focused on studying the roles of potassium ion channels on human T cells in human autoimmune diseases, and he holds a B.S. in Electrical Engineering from Stanford University.